Endotracheal News
-
N8 Medical Announces First-in-Human Use of its CeraShield™ Endotracheal Tube
N8 Medical, LLC (N8 Medical) today announced its first-in-human clinical trials of its flagship CeraShield™ endotracheal tube (CeraShield™ ETT) for intensive care unit patients expected to require mechanical ventilation for more than 48 hours. N8 Medical is encouraged by preliminary study data and believes that the CeraShield™ ETT will demonstrate safety and a significant ...
-
OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine
208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic therapy by 45%, shortened inappropriate antibiotic therapy by 39 hours, and reduced overall antibiotic therapy duration by 22.5% Unyvero results combined with antibiotic stewardship are efficient and safe in decreasing time on inappropriate ...
By OpGen, Inc.
-
Topline results from Phase 3 SPRINTER trial
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. SNG001 demonstrated a favourable safety profile and was well ...
-
N8 Medical Announces its CeraShield™ Coating inhibits COVID-19 Virus Growth on Endotracheal Tubes
N8 Medical, LLC, a privately held biotechnology company, today announced that its CeraShield™ coated endotracheal tubes significantly reduced the growth of COVID-19 virus in recent testing. The testing shows statistically significant reduction in the growth of the COVID-19 virus on the tube surface in 60 minutes. Ordinary uncoated endotracheal tubes either allowed increased virus growth or ...
-
Sommetrics and aerFree, LLC Contributing to Treatment of COVID-19
VISTA, Calif. — MAY 13, 2020 — Sommetrics, Inc. a company providing products and services to improve sleep quality, and its partially owned affiliate, aerFree, LLC, which is dedicated to improving acute airway management, today announced the donation of their aerFree® product to leading academic centers to assist in the management of COVID-19 respiratory impairment. aerFree® ...
By Sommetrics
-
Health Canada Grants Emergency Use Authorization for N8 Medical CeraShield™ Endotracheal Tubes in Mechanically Ventilated COVID-19 Patients
N8 Medical, LLC (N8 Medical) today announced that Health Canada has granted Dr. John Muscedere of Kingston General Hospital’s emergency request to begin using the N8 Medical CeraShield™ Endotracheal Tubes in mechanically-ventilated COVID-19 patients. N8 Medical’s CeraShield™ Endotracheal Tube has a patented anti-fouling coating that is designed to prevent deadly bacterial ...
-
Frost & Sullivan awards N8 Medical New Product Innovation Award for its Platform Medical Device Technology to Prevent Hospital-Acquired Infections
N8 Medical, LLC (N8 Medical) today announced it has been selected as the winner of a North American New Product Innovation Award by Frost & Sullivan, a leader in global research and consulting solutions. N8 Medical is developing disruptive medical devices that prevent hospital-acquired infections and their expensive and potentially fatal consequences. N8 Medical earned the award for its ...
-
Published Research Shows CSA-131’s Potent Efficacy against Global Health Threat
N8 Medical, LLC today announced a peer-reviewed publication in The Journal of Antimicrobial Chemotherapy with U.S. Centers for Disease Control and Prevention (CDC) co-authors of promising efficacy data regarding the activity of ceragenin CSA-131 against 100 strains of Candida auris (C. auris) collected from around the world. C. auris is a highly virulent and lethal pathogen of key clinical ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you